Treace Medical Beats Q1 Revenue Estimates, Narrows Loss to $0.28/Share
TMCI sits 71% above its 52-week low of $1.17.
Summary
Treace Medical Concepts reported a Q1 EPS loss of $0.28 per share, which is better than the $0.31 per share loss analysts had forecasted. The company also exceeded revenue expectations, reporting $47.198 million against an IBES estimate of $46 million. This news provides the actual financial results following a Reuters report two days prior that only provided analyst forecasts. Beating both top-line and bottom-line expectations is a significant positive catalyst for a company, particularly one of this market capitalization, and could lead to upward pressure on the stock price. Traders will now focus on the company's full earnings report and any updated guidance.
At the time of this announcement, TMCI was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.4M. The 52-week trading range was $1.17 to $7.78. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.